Show simple item record

dc.rights.licenceAttribution-NonCommercial 4.0 International*
dc.contributor.authorPontificia Universidad Javeriana. Facultad de Medicina. Departamento de Epidemiología Clínica y Bioestadística
dc.contributor.authorLasalvia, Pieralessandro
dc.contributor.authorHernández, Fabián
dc.contributor.authorCastañeda-Cardona, Camilo
dc.contributor.authorCuestas, Andrés
dc.contributor.authorRosselli, Diego
dc.coverage.spatialColombiaspa
dc.date.accessioned2020-09-17T00:23:53Z
dc.date.available2020-09-17T00:23:53Z
dc.date.created2020-01-28
dc.identifierhttps://www-sciencedirect-com.ezproxy.javeriana.edu.co/science/article/pii/S2212109919306272?via%3Dihubspa
dc.identifier.issn2212-11028 / 2212-1099 (Electrónico)spa
dc.identifier.urihttp://hdl.handle.net/10554/51082
dc.formatPDFspa
dc.format.mimetypeapplication/pdfspa
dc.languageInglésspa
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/*
dc.sourceValue in Health Regional Issues; Vol. 23 (2020)spa
dc.titleCost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombiaspa
dc.typeinfo:eu-repo/semantics/article
dc.type.hasversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.description.quartilescopusQ1spa
dc.identifier.doihttps://doi.org/10.1016/j.vhri.2019.08.481spa
dc.description.tipoarticuloArtículo completospa
dc.description.paginas13-18spa
dc.format.soporteElectrónicospa
dc.subject.keywordCost-effectivenessspa
dc.subject.keywordFingolimodspa
dc.subject.keywordMultiple sclerosisspa
dc.subject.keywordNatalizumabspa
dc.subject.keywordRelapsing-remittingspa
dc.description.abstractenglishObjectives: Multiple sclerosis (MS) is a degenerative neurological disorder. Treatment aims to avoid relapses and disability progression. The purpose of this study was to evaluate the cost-effectiveness of natalizumab compared with fingolimod for treating highly active relapsing-remitting MS (RRMS) patients from the Colombian third-party payer perspective. Methods: We used a Markov economic model from the perspective of the Colombian healthcare system to estimate the costeffectiveness of natalizumab compared with fingolimod for RRMS with high disease activity or failure of interferons as firstline therapy. This model was centered on disability progression and relapses. We considered a 5-year time horizon with a 5% discount rate. We included only direct medical costs. Local experts were consulted to obtain resource utilization estimates, and local standardized costing methodologies and sources were used. Outcome was considered in terms of quality-adjusted life-years (QALYs). Utilities were extracted or calculated from the literature. Transition probabilities were calculated from available efficacy and safety information (1 USD = 3050.98 COP). Results: Natalizumab showed lower total costs (USD 80 024 vs USD 98 137) and higher QALY yield (3.01 vs 2.94) than fingolimod, dominating it (incremental cost-effectiveness ratio = 2$1861). Univariate sensitivity analysis showcased the relevance of the measures of effect on disability progression for natalizumab on model results. Probabilistic sensitivity analysis replicated base-case results in most simulations. Conclusions: This study showed that natalizumab dominated fingolimod with lower costs and higher QALYs in patients with high-activity RRMS. These results are consistent with previous published international literature.spa
dc.type.localArtículo de revistaspa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial 4.0 International